Antisense Oligonucleotide STAT3 Inhibition Low Dose Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for B-cell lymphoma, particularly diffuse large B-cell lymphoma, are limited by high doses of antisense oligonucleotides required for efficacy, with LY2275796 showing no tumor response at 1,000 mg even with maximum tolerable and biologically effective doses.
Innovation Solution
Administration of a single-stranded modified oligonucleotide complementary to human STAT3, comprising a 16-nucleotide sequence with a gap segment and wing segments, linked by phosphorothioate internucleosides, at significantly lower doses (0.2-3.5 mg/kg/week) to inhibit STAT3 mRNA and protein expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of antisense oligonucleotides are administered to achieve tumor response, then therapeutic efficacy is improved, but toxicity and side effects increase
Solution Approach 1:
The patent changes the chemical parameters of the oligonucleotide by incorporating modified nucleosides (2'-O-methoxyethyl, bicyclic sugar) and phosphorothioate linkages, which alter the molecular properties to achieve both high efficacy and reduced toxicity at lower doses
Solution Approach 2:
The patent creates a composite oligonucleotide structure combining multiple modified components (different nucleoside modifications, phosphorothioate backbone) to achieve synergistic effects that improve therapeutic index
2Reliability
If maximum tolerable doses are administered to achieve biologically effective results, then therapeutic effect is improved, but treatment cost and burden increase
Solution Approach 1:
The patent modifies the oligonucleotide parameters to increase potency, enabling effective treatment at 0.2-3.5 mg/kg/week compared to the 1,000 mg doses required by previous compounds
3Adaptability or versatility
If conventional antisense oligonucleotides are used to target STAT3, then therapeutic approach is established, but tumor response is insufficient
Solution Approach 1:
The patent changes the chemical structure parameters of the oligonucleotide to improve target binding affinity and biological activity, resulting in significant tumor response where conventional approaches failed
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively treats B-cell lymphoma with unexpectedly low doses, reducing tumor size and prolonging survival, while being tolerable, as demonstrated by the use of a specific antisense compound targeting STAT3 in both loading and maintenance phases.
Implementation Method 1
a single-stranded modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of SEQ ID NO: 12
Implementation Method 2
wherein each intemucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage
Implementation Method 3
wherein each nucleoside of each wing segment comprises a constrained ethyl nucleoside
Data Source
AI summary
In certain embodiments, methods, compounds, and compositions for treating B-cell lymphoma or hepatocellular carcinoma by inhibiting expression of ST AT3 mRNA or protein in an animal are provided herein. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate B-celllymphoma or hepatocellular carcinoma. The STAT (signal transducers and activators of transcription) family of proteins are DNA-binding proteins that play a dual role in signal transduction and activation of transcription.